Rubidium-82 generator based on sodium nonatitanate support, and improved separation methods for the recovery of strontium-82 from irradiated targets
View Patent ↗Sodium nonatitanate compositions, a method using the composition for recovery of 82 Sr from irradiated targets, and a method using the composition for generating 82 Rb. The sodium nonatitanate materials of the invention are highly selective at separating strontium from solutions derived from the dissolution of irradiated target materials, thus reducing target processing times. The compositions also have a very low affinity for rubidium, making it an ideal material for use as a 82 Rb generator. Sodium nonatitanate materials of this type both improve the recovery of 82 Sr and provide a safer, more effective 82 Rb generator system.
1. A process for preparing a rubidium-82 generator, comprising:
preparing sodium nonatitanate from titanium isopropoxide and aqueous sodium hydroxide;
heating the sodium nonatitanate at a temperature between 100° C. and 250° C. for a period between 12 hours and 2 weeks;
lowering the pH of the sodium nonatitanate; and
absorbing strontium-82 on the neutralized sodium nonatitanate from an aqueous solution comprising strontium-82 and a soluble sodium salt.
2. The method of claim 1 , wherein the soluble sodium salt concentration is between about 0.1 and about 1 molar.
3. The process of claim 1 , wherein the soluble sodium salt is sodium chloride.
4. The process of claim 1 , wherein the molar ratio of aqueous sodium hydroxide to titanium isopropoxide is in excess of 0.44.
5. The process of claim 1 , wherein the molar ratio of aqueous sodium hydroxide to titanium isopropoxide is between 2 and 6.
6. The process of claim 1 , wherein the aqueous sodium hydroxide is about 50 wt % sodium hydroxide.
7. The process of claim 1 , further comprising:
filtering the sodium nonatitanate from the solution.
8. The process of claim 7 , further comprising:
washing the sodium nonatitanate with ethanol.
9. The process of claim 8 , further comprising:
drying the sodium nonatitanate.
10. The process of claim 1 , wherein the molar ratio of aqueous sodium hydroxide to titanium isopropoxide is between about 1 and 10.
11. The process of claim 1 , wherein the sodium nonatitanate is heated in a pressure vessel.
12. The process of claim 1 , wherein the sodium nonatitanate is prepared in the absence of titanium chlorides and sulfates.
13. The process of claim 1 , wherein the step of neutralizing the sodium nonatitanate further comprises:
suspending the sodium nonatitanate in a liquid; and
adding an acid to the liquid to lower the pH.
14. The process of claim 13 , wherein the step of adding an acid lowers the pH to between about 7 and about 9.
15. The process of claim 13 , wherein the step of adding and acid lowers the pH to between about 7 and about 8.3.
16. The process of claim 13 , wherein the liquid comprises water.
17. The process of claim 13 , wherein the acid is a strong mineral acid.
18. The process of claim 1 , further comprising:
loading the sodium nonatitanate into a column.
19. The process of claim 1 , further comprising:
supporting the sodium nonatitanate on a non-porous substrate.
20. The process of claim 1 , wherein the solution containing strontium-82 is an acidic aqueous solution.
21. A process for preparing a solution containing rubidium-82, comprising:
providing a solution containing strontium-82;
absorbing strontium-82 onto a sodium nonatitanate support medium;
eluting rubidium-82 from the sodium nonatitanate support medium with an eluant;
receiving a rubidium-82 eluate from the sodium nonatitanate support medium; and
adjusting a pH of the eluate.
22. The process of claim 21 , wherein the eluant is selected from the group consisting of water and saline solutions.
23. The process of claim 21 , wherein the eluant is an aqueous solution having a sodium chloride concentration between 0.001 molar and 1 molar.
24. The process of claim 21 , wherein the eluant is an aqueous solution having a sodium chloride concentration between 0.2 molar and 1 molar.
25. The process of claim 21 , wherein the eluant is a pharmaceutical-grade saline and buffer solution.
26. The process of claim 21 , wherein the sodium nonatitanate is characterized by a strontium/rubidium separation factor greater than 12,500.
27. The process of claim 21 , wherein the sodium nonatitanate is characterized by a strontium/rubidium separation factor greater than or equal to 59,200.
28. The process of claim 21 , wherein the sodium nonatitanate is characterized by a strontium/rubidium separation factor greater than or equal to 100,000.
29. The process of claim 21 , further comprising:
disposing the sodium nonatitanate support medium into a column.
30. The process of claim 21 , wherein the eluate is alkaline.
31. The process of claim 21 , further comprising:
buffering the solvent.
32. The process of claim 21 , wherein the pH of the eluate is adjusted to between about 4.5 and about 7.
33. The process of claim 21 , wherein the pH of the eluate is adjusted to a pH suitable for injecting into a patient during a medical procedure.
34. The process of claim 21 , wherein the step of adjusting a pH of the eluate comprises;
adding an acid to the eluate.
35. The process of claim 34 , wherein the acid is HCl.
36. The process of claim 21 , further comprising:
partially neutralizing the sodium nonatitanate before the step of absorbing strontium-82 onto a sodium nonatitanate support medium.
37. A process for preparing a rubidium-82 generator, comprising:
preparing sodium nonatitanate from titanium tetrachloride or titanium sulfate and aqueous sodium hydroxide;
heating the sodium nonatitanate at a temperature between 100° C. and 250° C. for a period between 12 hours and 2 weeks;
lowering the pH of the sodium nonatitanate; and then
absorbing strontium-82 on the sodium nonatitanate from an aqueous solution comprising strontium-82 and a soluble sodium salt.
38. The process of claim 37 , wherein the soluble sodium salt concentration is between about 0.1 and about 1 molar.
39. The process of claim 37 , wherein the soluble sodium salt is sodium chloride.
40. The process of claim 37 , wherein the aqueous sodium hydroxide is about 50 wt % sodium hydroxide.
41. The process of claim 37 , wherein the molar ratio of aqueous sodium hydroxide to titanium tetrachloride or titanium sulfate is between about 1 and 12.
42. The process of claim 37 , further comprising:
filtering to collect the sodium nonatitanate; and
washing the sodium nonatitanate to remove sodium chloride or sodium sulfate.
43. The process of claim 37 , wherein lowering the pH of the sodium nonatitanate further comprises:
suspending the sodium nonatitanate in a liquid; and
adding an acid to the liquid to lower the pH.
44. The process of claim 43 , wherein adding the acid lowers the pH to between about 7 and about 9.
45. The process of claim 43 , wherein adding the acid lowers the pH to between about 7.2 and about 8.
46. The process of claim 43 , wherein the liquid comprises water.
47. The process of claim 43 , wherein the acid is a strong mineral acid.
48. The process of claim 37 , further comprising:
loading the sodium nonatitanate into a column.
49. The process of claim 37 , further comprising:
supporting the sodium nonatitanate on a substrate.
50. The process of claim 37 , wherein the solution containing strontium-82 is an acidic aqueous solution.
51. A process, comprising:
eluting a solution of rubidium-82 from a strontium-82 support medium comprising sodium nonatitanate with an aqueous eluant; and
adjusting a pH of the solution.
52. The process of claim 51 , wherein the aqueous eluant is selected from the group consisting of water and saline solutions.
53. The process of claim 51 , wherein the aqueous eluant has a sodium chloride concentration between 0.001 molar and 1 molar.
54. The process of claim 51 , wherein the aqueous eluant has a sodium chloride concentration between 0.2 molar and 1 molar.
55. The process of claim 51 , wherein the aqueous eluant is a saline and buffer solution suitable for human injection.
56. The process of claim 51 , wherein the sodium nonatitanate is a reaction product of titanium isopropoxide and aqueous sodium hydroxide.
57. The process of claim 51 , further comprising passing the rubidium-82 solution through a sodium nonatitanate filter to selectively remove any strontium-82 or strontium-85 from the solution.
58. The process of claim 57 , further comprising disposing of the sodium nonatitanate filter.
59. The process of claim 51 , further comprising using the rubidium-82 solution as a medical diagnostic agent or medical imaging agent.
60. The process of claim 59 , further comprising injecting the rubidium-82 solution intravenously.
61. The process of claim 51 , further comprising stripping strontium-82 from the sodium nonatitanate.
62. The process of claim 61 , further comprising recovering the stripped strontium-82.
63. The process of claim 62 , further comprising recycling the sodium nonatitanate.
64. The process of claim 51 , wherein the sodium nonatitanate has not undergone hydrothermal treatment.
65. The process of claim 51 wherein the step of adjusting the pH further comprises:
adding an acid to the solution.
66. The process of claim 51 , wherein the pH is adjusted to between about 4 and about 7.5.